$19.41
0.130.67%
At close: -
$19.41
0.000.00%
After Hours: 4:01 PM EDT
Comments
Loading...
Rigel Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RIGL | Benzinga
Rigel Pharmaceuticals Inc has a consensus price target of $27 based on the ratings of 7 analysts. The high is $57 issued by HC Wainwright & Co. on March 5, 2025. The low is $2 issued by Piper Sandler on August 17, 2022. The 3 most-recent analyst ratings were released by Citigroup, B. Riley Securities, and HC Wainwright & Co. on March 6, 2025, March 5, 2025, and March 5, 2025, respectively. With an average price target of $45.33 between Citigroup, B. Riley Securities, and HC Wainwright & Co., there's an implied 133.56% upside for Rigel Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
B. Riley Securities
HC Wainwright & Co.
Cantor Fitzgerald
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Rigel Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | 183.36% | Citigroup | Yigal Nochomovitz57% | $49 → $55 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 23.65% | B. Riley Securities | Kalpit Patel41% | $20 → $24 | Maintains | Neutral | Get Alert |
| 03/05/2025 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2025 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 28.8% | Cantor Fitzgerald | Kristen Kluska68% | $15 → $25 | Maintains | Neutral | Get Alert |
| 12/10/2024 | Buy Now | 3.04% | B. Riley Securities | Kalpit Patel41% | $27 → $20 | Maintains | Neutral | Get Alert |
| 12/10/2024 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | 39.1% | B. Riley Securities | Kalpit Patel41% | $17 → $27 | Maintains | Neutral | Get Alert |
| 11/14/2024 | Buy Now | 18.5% | Piper Sandler | Allison Bratzel64% | $15 → $23 | Maintains | Neutral | Get Alert |
| 11/12/2024 | Buy Now | 152.45% | Citigroup | Yigal Nochomovitz57% | $40 → $49 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | -22.72% | Cantor Fitzgerald | Kristen Kluska68% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 09/05/2024 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 193.66% | HC Wainwright & Co. | Joseph Pantginis45% | $15 → $57 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | -79.39% | Citigroup | Yigal Nochomovitz57% | $30 → $40 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $15 → $150 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | -84.54% | Cantor Fitzgerald | Kristen Kluska68% | $20 → $30 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | -93.56% | B. Riley Securities | Kalpit Patel41% | $12.5 → $12.5 | Maintains | Neutral | Get Alert |
| 02/22/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $15 → $150 | Reiterates | Buy → Buy | Get Alert |
| 01/04/2024 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $15 → $150 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $150 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | Buy Now | -89.7% | Piper Sandler | Allison Bratzel64% | → $20 | Assumes | → Neutral | Get Alert |
| 03/09/2023 | Buy Now | -84.54% | Citigroup | Yigal Nochomovitz57% | $20 → $30 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $150 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | Buy Now | — | Citigroup | Yigal Nochomovitz57% | — | Upgrade | Neutral → Buy | Get Alert |
| 11/04/2022 | Buy Now | -84.54% | BMO Capital | Gary Nachman58% | $40 → $30 | Maintains | Outperform | Get Alert |
| 08/18/2022 | Buy Now | -22.72% | HC Wainwright & Co. | Joseph Pantginis45% | $70 → $150 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | -89.7% | Piper Sandler | Do Kim54% | $10 → $20 | Maintains | Neutral | Get Alert |
| 06/09/2022 | Buy Now | -84.54% | BMO Capital | Gary Nachman58% | $70 → $30 | Maintains | Outperform | Get Alert |
| 06/09/2022 | Buy Now | -93.56% | B. Riley Securities | Kalpit Patel41% | $40 → $12.5 | Maintains | Neutral | Get Alert |
| 06/09/2022 | Buy Now | -95.88% | Citigroup | Yigal Nochomovitz57% | $70 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 06/08/2022 | Buy Now | -63.94% | HC Wainwright & Co. | Joseph Pantginis45% | $110 → $70 | Maintains | Buy | Get Alert |
| 06/08/2022 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | — | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for Rigel Pharmaceuticals (RIGL) stock?
The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by Citigroup on March 6, 2025. The analyst firm set a price target for $55.00 expecting RIGL to rise to within 12 months (a possible 183.36% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ:RIGL) was provided by Citigroup, and Rigel Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rigel Pharmaceuticals (RIGL)?
The last upgrade for Rigel Pharmaceuticals Inc happened on December 2, 2022 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for Rigel Pharmaceuticals Inc.
When was the last downgrade for Rigel Pharmaceuticals (RIGL)?
The last downgrade for Rigel Pharmaceuticals Inc happened on June 9, 2022 when Citigroup changed their price target from $7 to $0.8 for Rigel Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a maintained with a price target of $49.00 to $55.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $19.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
